Company Overview of MyoKardia, Inc.
MyoKardia, Inc. develops a pipeline of small molecule therapeutics that address key clinical needs for patients with genetic heart disease. The company was founded in 2012 and is based in San Francisco, California.
455 Mission Bay Boulevard South
San Francisco, CA 94158
Founded in 2012
Key Executives for MyoKardia, Inc.
Chief Executive Officer and Director
Compensation as of Fiscal Year 2014.
MyoKardia, Inc. Key Developments
MyoKardia, Inc Appoints Mark L. Perry to Board of Directors
Nov 25 13
MyoKardia, Inc. announced the appointment of Mark L. Perry to its board of directors, joining Tassos Gianakakos, Charles Homcy, M.D., and Kevin Starr. Mr. Perry currently serves as chairman of the board of Pathway Therapeutics and director of Nvidia Corporation. Mr. Perry is also a member of the California State Bar Association and the Association of Bioscience Financial Officers, and serves on several nonprofit boards.
MyoKardia, Inc. Announces Management Changes
Oct 30 13
MyoKardia, Inc. announced the appointment of Tassos Gianakakos to chief executive officer. Mr. Gianakakos succeeds founding CEO Charles Homcy, M.D., who will remain on MyoKardia's board of directors. Mr. Gianakakos brings more than 17 years of broad-based biopharmaceutical expertise to MyoKardia. He joins the company from MAP Pharmaceuticals, where he was most recently senior vice president and chief business officer.
MyoKardia, Inc. Appoints Jonathan C. Fox, M.D., Ph.D., as Chief Medical Officer
Jan 30 13
MyoKardia, Inc. announced the appointment of Jonathan C. Fox, M.D., Ph.D., as Chief Medical Officer. In his role, Dr. Fox will be responsible for the clinical development and regulatory strategy for MyoKardia's pipeline of novel, small molecule therapeutics focused on treatments for genetically determined hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Dr. Fox brings to MyoKardia working knowledge across all phases of clinical development, from clinical pharmacology to large cardiovascular outcomes trials. In his previous roles with top tier global biopharmaceutical companies, Dr. Fox led clinical research teams that secured multiple cardiometabolic drug product approvals. Before joining MyoKardia, he served as Vice President of Clinical Development at AstraZeneca; Senior Director, Clinical Cardiovascular Research at Merck; and Director of Clinical Pharmacology at SmithKline Beecham.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|